Protein-protein interactions (PPIs) are classically considered to be ‘undruggable’ targets. However, with up to 650,000 of them in the human interactome, they are an attractive option when considering novel therapeutic targets. By 2011, only approximately 2% of PPIs had been targeted with drugs. Over the last decade, PPIs have been turned to more and more for precision treatments of diseases in which therapeutic options are limited. They underpin many important cellular processes, however, they are difficult to study, thus have remained elusive and not fully understood. The potential for PPIs in discovering novel drug candidates is immense, however, novel screening...
To view this content, please register now for access
Become a member of BioTechniques for FREE to receive:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!